A US randomized clinical trial suggested that early time-restricted eating (eTRE) was more effective for weight loss than eating over a window of 12 or more hours. A total of 90 obese participants (mean body mass index, 39.6; age, 43 years; 80% female) received weight-loss treatment (energy restriction [ER] of 500 calories per day below their resting energy expenditure and exercised for 75 to 150 minutes per week) and were randomized to eTRE plus ER (8-hour eating window from 7:00 to 15:00) or control eating (CON) plus ER (≥12-hour window). The eTRE+ER group adhered 6.0 days per week. At 14 weeks, the eTRE+ER intervention was more effective for losing weight (−2.3 kg; P = .002) but did not significantly affect body fat (−1.4 kg; P = .09) or the ratio of fat loss to weight loss (−4.2%; P = .43). The effects of eTRE+ER were equivalent to reducing calorie intake by an additional 214 kcal/d. The eTRE+ER intervention also improved diastolic blood pressure (−4 mm Hg; P = .04) and mood disturbances, including fatigue-inertia, vigor-activity, and depression-dejection. All other cardiometabolic risk factors, food intake, physical activity, and sleep outcomes were similar between groups. In a secondary analysis of 59 completers, eTRE+ER was also more effective for losing body fat and trunk fat than CON+ER. The findings support a time-restricted diet in addition to calorie restriction for weight loss although there are some inconsistencies with previous similar studies. Source: https://jamanetwork.com/
Early-life sugar restriction during pregnancy and infancy was associated with a 34% lower risk of…
Higher levels of physical activity were associated with lower risks of all-cause dementia, Alzheimer’s disease,…
In US adults aged ≥65 years, overweight and class I–II obesity were associated with lower…
In community-dwelling older adults without prior cardiovascular disease (CVD), new or persistent heart stress (HS)—defined…
In the German multicenter study of 5,521 patients with colorectal cancer (CRC), the apparent survival…
In adults aged 75 years or older without a history of atherosclerotic cardiovascular disease (ASCVD)…
This website uses cookies.